Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Assistance Publique - Hôpitaux de Paris maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently features 1 pending office action, which represents the sole focus of its active prosecution. This action is handled by 1 distinct examiner, COUNTS, GARY W, who is the only examiner currently assigned to the company's applications.
The activity is confined to 1 distinct art unit. This concentration suggests that the company's innovations in biotechnology or pharmaceuticals are being reviewed within a specific technical group. COUNTS, GARY W is the busiest examiner for the portfolio, with 1 pending office action. This examiner's individual review will determine the immediate outcome for the pending matter.
Since there is only 1 pending office action, the busiest examiner's load represents the total active workload for the portfolio. This one-to-one relationship simplifies the management of the patenting process. Practitioners can concentrate their efforts on understanding the specific examination patterns of COUNTS, GARY W, as there are no other pending actions to consider. This centralized structure allows for a highly targeted prosecution strategy within the single art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §112 only | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WARD, PAUL V | 1 | 83.2% | -12.2% |
| GIBBS, TERRA C | 1 | 63.7% | +10.3% |
| SIMMONS, VALERIE MICHELLE | 1 | 28.9% | +46.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18838160 | AMILORIDE FOR USE IN THE TOPICAL TREATMENT OF SOMATOSENSORY IMPAIRMENTS | WARD, PAUL V | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17293602 | METHOD FOR DETERMINING ONE CONTENT IN PROTEIN AND ASSOCIATED DEVICES AND METHODS | SIMMONS, VALERIE MICHELLE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18305809 | METHODS FOR PERFORMING ANTISENSE OLIGONUCLEOTIDE-MEDIATED EXON SKIPPING IN THE RETINA OF A SUBJECT IN NEED THEREOF | GIBBS, TERRA C | 121d overdue |
| 17293602 | METHOD FOR DETERMINING ONE CONTENT IN PROTEIN AND ASSOCIATED DEVICES AND METHODS | SIMMONS, VALERIE MICHELLE | — |
| Art Unit | Apps |
|---|---|
| 1635 | 1 |
| 1758 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18838160 | AMILORIDE FOR USE IN THE TOPICAL TREATMENT OF SOMATOSENSORY IMPAIRMENTS | WARD, PAUL V | — | §112 | Non-Final OA | — | Pending | Aug 13, 2024 |
| 18305809 | METHODS FOR PERFORMING ANTISENSE OLIGONUCLEOTIDE-MEDIATED EXON SKIPPING IN THE RETINA OF A SUBJECT IN NEED THEREOF | GIBBS, TERRA C | 1635 | §112 | Final Rejection | 121d overdue | Pending | Apr 24, 2023 |
| 17293602 | METHOD FOR DETERMINING ONE CONTENT IN PROTEIN AND ASSOCIATED DEVICES AND METHODS | SIMMONS, VALERIE MICHELLE | 1758 | §101§103 | Non-Final OA | — | Pending | May 13, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial